DOI QR코드

DOI QR Code

Bioequivalence of GLUNATE® Tablet to PASTIC® Tablet (nateglinide 90 mg)

파스틱 정®(나테글리니드 90 mg)에 대한 글루나테 정®의 생물학적 동등성

  • Published : 2009.04.27

Abstract

The purpose of this study was to evaluate the bioequivalence of two nateglinide tablets, $PASTIC^{(R)}$ tablet (ILDONG Pharm. Co., Ltd., Seoul, Korea, reference drug) and $GLUNATE^{(R)}$ tablet (ILHWA. Co., Ltd., Seoul, Korea, test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Thirty-five healthy male volunteers, $23.1{\pm}2.3$ years in age and $69.2{\pm}8.8\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After a tablet containing 90 mg of nateglinide was orally administrated, blood was taken at predetermined time intervals over a period of 8 hr and concentrations of nateglinide in plasma were monitored using LC-MS/MS. Pharmacokinetic parameters such as AUCt (the area under the plasma concentration-time curve from time 0 to 8 hr), $C_{max}$ (maximum plasma drug concentration) and $TC_{max}$ (time to reach $CC_{max}$) were calculated and analysis of variance (ANOVA) test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$ and $C_{max}$ and untransformed $T_{max}$. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $GLUNATE^{(R)}/PASTIC^{(R)}$ were ${\log}1.0782{\sim}{\log}1.1626$ and ${\log}0.9621{\sim}{\log}1.1679$, respectively. Since these values were within the acceptable bioequivalence intervals of ${\log}0.80{\sim}{\log}1.25$, recommended by KFDA, it was concluded that $GLUNATER^{(R)}$ tablet was bioequivalent to $PASTIC^{(R)}$ tablet, in terms of both rate and extent of absorption.

Keywords

References

  1. Y.H. Walter, D.I. Spratt, S. Garreffa and J.F. McLeod, Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus, Eur. J. Clin. Pharmacol., 56, 129-133 (2000). https://doi.org/10.1007/s002280050730
  2. Y. Hirschberg, A.O Pietri, A.D. Karara and J.F. Mcleod, Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin, Diabetes Care, 23, 349-353 (2000). https://doi.org/10.2337/diacare.23.3.349
  3. D. Anderson, S. Shelley, N. Kellett, D. Marshall and W. Nimmo, The effect of nateglinide taken with food on gastric emptying rates in healthy subjects, Clin. Ther., 25, 1722-1738 (2003). https://doi.org/10.1016/S0149-2918(03)80165-0
  4. 식품의약품안전청 고시 제 2007-65호(2007. 09. 20), 생물학적동등성시험기준.
  5. 식품의약품안전청 고시 제 2007-34호(2007. 05. 31), 의약품임상시험관리기준.
  6. S. Bauer, E. Stormer, J. Kirchheiner, C. Michael, J. Brockmoller and I. Roots, Rapid and Simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection, J. Pharm. Biomed. Anal., 31, 551-555 (2003). https://doi.org/10.1016/S0731-7085(02)00680-5
  7. M.L. Weaver, B.A. Orwig, L.C. Rodriguez, E.D. Graham, J.A. Chin, M.J. Shapiro, J.F. Mcleod and J.B. Mangold, Pharmacokinetics and metabolism of nateglinide in humans, Drug Metab. Dispos., 29, 415-421 (2001).